<VariationArchive VariationID="617505" VariationName="NM_172107.4(KCNQ2):c.958_993dup (p.Val320_Lys331dup)" VariationType="Duplication" Accession="VCV000617505" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2019-01-31" MostRecentSubmission="2019-01-31">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="608865" VariationID="617505">
      <GeneList>
        <Gene Symbol="KCNQ2" FullName="potassium voltage-gated channel subfamily Q member 2" GeneID="3785" HGNC_ID="HGNC:6296" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20q13.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="63400208" stop="63472655" display_start="63400208" display_stop="63472655" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NT_187625.1" start="183" stop="33239" display_start="183" display_stop="33239" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="62037541" stop="62103992" display_start="62037541" display_stop="62103992" Strand="-" />
          </Location>
          <OMIM>602235</OMIM>
          <Haploinsufficiency last_evaluated="2013-07-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KCNQ2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-07-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=KCNQ2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_172107.4(KCNQ2):c.958_993dup (p.Val320_Lys331dup)</Name>
      <CanonicalSPDI>NC_000020.11:63438654:CTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAACCTTC:CTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAACCTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAACCTTC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>20q13.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="63438654" stop="63438655" display_start="63438654" display_stop="63438655" variantLength="36" positionVCF="63438654" referenceAlleleVCF="T" alternateAlleleVCF="TCTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAAC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="62070007" stop="62070008" display_start="62070007" display_stop="62070008" variantLength="36" positionVCF="62070007" referenceAlleleVCF="T" alternateAlleleVCF="TCTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAAC" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.62070012_62070047dup" Assembly="GRCh37">
            <Expression>NC_000020.10:g.62070012_62070047dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.63438659_63438694dup" Assembly="GRCh38">
            <Expression>NC_000020.11:g.63438659_63438694dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009004.2" sequenceAccession="NG_009004" sequenceVersion="2" change="g.38951_38986dup">
            <Expression>NG_009004.2:g.38951_38986dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004518.6" sequenceAccession="NM_004518" sequenceVersion="6" change="c.958_993dup">
            <Expression>NM_004518.6:c.958_993dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004509.2" sequenceAccession="NP_004509" sequenceVersion="2" change="p.Val320_Lys331dup">
            <Expression>NP_004509.2:p.Val320_Lys331dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172106.3" sequenceAccession="NM_172106" sequenceVersion="3" change="c.958_993dup">
            <Expression>NM_172106.3:c.958_993dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_742104.1" sequenceAccession="NP_742104" sequenceVersion="1" change="p.Val320_Lys331dup">
            <Expression>NP_742104.1:p.Val320_Lys331dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172107.4" sequenceAccession="NM_172107" sequenceVersion="4" change="c.958_993dup" MANESelect="true">
            <Expression>NM_172107.4:c.958_993dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_742105.1" sequenceAccession="NP_742105" sequenceVersion="1" change="p.Val320_Lys331dup">
            <Expression>NP_742105.1:p.Val320_Lys331dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172108.5" sequenceAccession="NM_172108" sequenceVersion="5" change="c.958_993dup">
            <Expression>NM_172108.5:c.958_993dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_742106.1" sequenceAccession="NP_742106" sequenceVersion="1" change="p.Val320_Lys331dup">
            <Expression>NP_742106.1:p.Val320_Lys331dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_172109.3" sequenceAccession="NM_172109" sequenceVersion="3" change="c.958_993dup">
            <Expression>NM_172109.3:c.958_993dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_742107.1" sequenceAccession="NP_742107" sequenceVersion="1" change="p.Val320_Lys331dup">
            <Expression>NP_742107.1:p.Val320_Lys331dup</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1568925507" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="probably has functional consequence" />
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_172107.4(KCNQ2):c.958_993dup (p.Val320_Lys331dup) AND Developmental and epileptic encephalopathy, 7" Accession="RCV000754629" Version="3">
        <ClassifiedConditionList TraitSetID="6737">
          <ClassifiedCondition DB="MedGen" ID="C3150986">Developmental and epileptic encephalopathy, 7</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2018-10-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-10-24" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-01-31" MostRecentSubmission="2019-01-31">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">32585800</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6737" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15768" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">KCNQ2-Related Neonatal Epileptic Encephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Early infantile epileptic encephalopathy 7</ElementValue>
                <XRef ID="Epileptic+encephalopathy%2C+early+infantile%2C+7/8345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Developmental and epileptic encephalopathy, 7</ElementValue>
                <XRef ID="MONDO:0013387" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">DEE7</ElementValue>
                <XRef Type="MIM" ID="613720" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes ranging from self-limited familial neonatal epilepsy (SLFNE) at the mild end to neonatal-onset developmental and epileptic encephalopathy (NEO-DEE) at the severe end. Additional, less common phenotypes consisting of neonatal encephalopathy with non-epileptic myoclonus, infantile or childhood-onset developmental and epileptic encephalopathy (DEE), and isolated intellectual disability (ID) without epilepsy have also been described. KCNQ2-SLFNE is characterized by seizures that start in otherwise healthy infants between two and eight days after term birth and spontaneously disappear between the first and the sixth to 12th month of life. There is always a seizure-free interval between birth and the onset of seizures. Seizures are characterized by sudden onset with prominent motor involvement, often accompanied by apnea and cyanosis; video EEG identifies seizures as focal onset with tonic stiffening of limb(s) and some migration during each seizure's evolution. About 30% of individuals with KCNQ2-SLFNE develop epileptic seizures later in life. KCNQ2-NEO-DEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features. Seizures generally cease between ages nine months and four years. At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia hyperdensities and later MRIs may show white matter or general volume loss. Moderate-to-profound developmental impairment is present.</Attribute>
                <XRef ID="NBK32534" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13060" />
                <XRef ID="13060" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KCNQ2-Related Disorders</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20437616</ID>
                <ID Source="BookShelf">NBK32534</ID>
              </Citation>
              <XRef ID="439218" DB="Orphanet" />
              <XRef ID="C3150986" DB="MedGen" />
              <XRef ID="MONDO:0013387" DB="MONDO" />
              <XRef Type="MIM" ID="613720" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1727078" SubmissionDate="2020-07-16" DateLastUpdated="2019-01-31" DateCreated="2019-01-31">
        <ClinVarSubmissionID localKey="SUB5006273" submittedAssembly="GRCh37" title="SUB5006273" />
        <ClinVarAccession Accession="SCV000863983" DateUpdated="2019-01-31" DateCreated="2019-01-31" Type="SCV" Version="3" SubmitterName="Translational Oncology and Experimental Therapeutics Program-IBMCC, Consejo Superior de Investigaciones Científicas" OrgID="506795" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-10-24">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">32585800</ID>
          </Citation>
          <Comment>ACMG Guidelines, 2015 Method: clinical testing. The patient is a 6-year-old boy, second son of healthy parents, affected with an epileptic encephalopathy of neonatal onset and unknown origin. Pregnancy with gestational diabetes was controlled with diet. Delivery was uneventful. Since 48 hours of life, he presented episodes of cyanosis, generalized hypertonia, and tonic asymmetric postures followed by apnea. Video-EEG at 5 days of life showed bilateral and asynchronous spike-and-wave. Seizures were refractory to phenobarbital but were controlled with phenytoin. Since 3 months of age, he presented with startle episodes without EEG correlate related to the wake and sleep transition together with dystonic postures. One month later, epileptic spasms without hypsarrhythmia were observed. There was no response to levetiracetam and valproic acid but were stopped after lacosamide (LCS) treatment was initiated (11 months of age). Metabolic tests (including CSF studies), karyotype, and brain MRI were normal. Epileptic encephalopathy gene panel was negative including hyperekplexia related genes. Progressive increase of TSH was treated with oral L-t4. At 20 months he presented recurrence of spasms that were controlled with LCS dose adjustment. V-EEG showed an abnormal background activity, and paroxysmal multifocal discharges that showed activation and generalization during sleep. After several years of good seizure control, LCS was discontinued. He suffered from decompensation of seizures with febrile viral infection, and at 5 years of age he presented startle episodes associated to auditory stimulus without EEG correlate, but during sleep, he presented epileptic spasms with EEG correlate. Treatment with vigabatrine was initiated with a clinical and EEG improvement. Last v-EEG monitoring showed bilateral polyspike discharges and clinical spasms in polygraph recording without any clear EEG correlate. Many KCNQ2 encephalopathy patients present a very good response to sodium channel blockers, as our patient did with phenytoin in neonatal period and LCS later, treatment with LCS was reintroduced. At physical exam he presents severe axial hypotonia without head control, hypertonia of four limbs with dystonic movements of upper limbs, no hand use and is not able to sit or crawl. No development of expressive language. In the GMFCS (Gross Motor Function Classification System) scale the patient is in level V (Physical impairments restrict voluntary control of movement and the ability to maintain antigravity head and trunk postures. All areas of motor function are limited, children have no means of independent movement and are transported). This complex and severe neurodevelopmental syndrome could be due to the phenotypic convergence of several genetic alterations whose biological functions contribute to different aspects and the complexity of the clinical phenotype.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Somatic mutation</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>de novo</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Spain</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">0</Age>
              <Age Type="maximum" age_unit="years">9</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <NamePlatform>HiSeq</NamePlatform>
              <TypePlatform>Next-generation sequencing</TypePlatform>
              <Description>Matrix chip from Affymetrix CytoScan-HD. Matrixes were washed and stained in the GeneChip Fluidics Station 450 (Affymetrix Inc.) and DAT images were acquired with the GeneChip Scanner 3000 7G (Affymetrix Inc). DAT images were acquired with the GeneChip Scanner 3000 7G (Affymetrix Inc). The data files (archives.cel) were generated with the Affymetrix GeneChip Command Console Software (AGCC) software (Affimetrix Inc., Santa Clara, CA). Data analysis was performed using the analysis program package from Affymetrix Chromosome Analysis Suite (CHAS). The CGH results were compared with data in ChAs 3.3 NetAffix Build 33.2(Hg19) as reference. Variant is confirmed by DNA sequence.</Description>
              <MethodType>case-control</MethodType>
              <MethodAttribute>
                <Attribute Type="StructVarMethodType">Oligo array</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0001250" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0008936" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0002509" />
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0002451" />
              </Trait>
              <Comment>This complex and severe neurodevelopmental syndrome could be due to the phenotypic convergence of several genetic alterations whose biological functions contribute to different aspects and the complexity of the clinical phenotype. In this report, we have genetically studied the patient and his family by WES and aCGH.</Comment>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="KCNQ2">
              <Name>potassium voltage-gated channel subfamily Q member 2</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NC_000020.10: exon 7</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Lys331_Arg332insValGlnGluGlnHisArgGlnLysHisPheGluLys</Name>
          </OtherNameList>
          <FunctionalConsequence Value="probably has functional consequence" />
          <AttributeSet>
            <Attribute Type="HGVS">NC_000020.10:g.62070007_62070008insCTTCTCAAAGTGCTTCTGCCTGTGCTGCTCCTGAAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613720" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1727078" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002451" MappingRef="HP">
        <MedGen CUI="C0751093" Name="Limb dystonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1727078" TraitType="Finding" MappingType="XRef" MappingValue="HP:0008936" MappingRef="HP">
        <MedGen CUI="C1853743" Name="Axial hypotonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1727078" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002509" MappingRef="HP">
        <MedGen CUI="C1838391" Name="Limb hypertonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1727078" TraitType="Disease" MappingType="XRef" MappingValue="613720" MappingRef="OMIM">
        <MedGen CUI="C3150986" Name="Developmental and epileptic encephalopathy, 7" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1727078" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001250" MappingRef="HP">
        <MedGen CUI="C0036572" Name="Seizure" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

